Sonus Pharmaceuticals, a development company, is engaged in the research of proprietary contrast agents for use in ultrasound imaging.
The firm’s primary product under development is Echogen emulsion, a contrast agent to be administrated to a patient prior to performing Ultrasound studies to improve the quality of the ‘after-image’.
Sonus goal is to establish the use of Echogen in various radiological applications. Sonus contends the use of Echogen in some of the 28m yearly ultrasound studies will provide significant cost savings in comparison to other imaging studies such as MRI and CT imaging.
Echogen had completed its Phase III in radiology and cardiac function and should start a phase III for cardiac perfusion late this year. NDA is expected for 2nd half of 1996.
Echogen’s Phase III in radiology data were outstanding, showing dramatic ability to enhance visualization (94%) assist (73%) or change (11%) the doctor’s diagnosis.
Financial data:
Shares Outstanding (M): 8.5
Share price: 22 US$
Market cap: 187m US$
Revenue 95: 4.5
Net Income 95: (5.9)
If FDA approves Echogen, revenues should increase dramatically.
Any opinions out there on this company ?
(I’m in at 21 3/8) |
